Mégane Brusson received her Ph.D. in Genomes and Proteins in 2017 from Paris Diderot University. In Wassim El Nemer’s lab, she studied the role of JAK2V617F mutation and treatments by hydroxycarbamide and interferon-α on erythroid and endothelial abnormalities in Polycythemia Vera. From 2017-18, she was a lecturer at Versailles-Saint-Quentin-En-Yvelines University in Bernard Mignotte’s lab where she taught Genetics and studied the role of mitochondria in Rb-induced apoptosis in Drosophila. She joined the lab of Dr. Annarita Miccio in May 2018, where she developed a novel lentiviral vector, carrying gene addition and gene silencing functions, for gene therapy of β-hemoglobinopathies. Since 2020, she co-supervises the PhD project of Anne Chalumeau who aims to elaborate a universal genome editing approach for β-hemoglobinopathies using the prime editing technology. Finally, she is currently studying the gene expression signature at single cell level of erythroblast precursors from β-hemoglobinopathy patients to identify novel therapeutic targets.